Algernon Pharmaceuticals Inc (AGNPF)

[medchem]

Some DD.

For those who missed it this weekend. Check out my DD/previous post:

Morning read and DD!


For those who would like to know a little more about the solid science that STRONGLY supports the efficacy of our drug in treating lung disease, especially the advanced form of lung disease called "Acute Respiratory Distress Syndrome" or ARDS caused by viral illness in the lungs (e.g. coronavirus)....

Below is an exerpt from the recently published paper in 2019 in mSystems journal which describes how the scientists found Ifenprodil as the big hit in decreasing mortality (aka death) and decreasing the ARDS caused by severe viral illness.

Here is a short list, broken down into lay terms so you can understand. If you don't, just let me know and I will explain further. But remember, it is these scientific results that are the reason we feel that Algernon has hit the jackpot and is sitting on a multi-billion dollar drug.

All of my key points here are directly related to the highlighted/bolded text below in the quoted which I took directly from the journal article. If you want a copy of the journal article, just send me your email.

Key points summarized by medchem:

1. Ifenprodil helps keeps infected cells alive
2. Ifenprodil has low side effects and is safe (low cytotoxicity)
3. Ifenprodil improves survival in the context of severe viral illness
4. Ifenprodil decreases (ameliorates) acute lung injury which leads to ARDS (which prevents death)
5. Ifenprodil decreased the lung edema (fluid) caused by the ARDS (aka it decreased the factor that is responsible for ARDS killing so many patients)
6. Ifenprodil deceased the number of white blood cells (neutrophils), natural killer cells, and t-cells (these are the parts of the immune system that attack the lungs with ARDS). Decreasing these decreases INFLAMMATION and gives the lungs a chance to heal.
7. Ifenprodil decreased the cytokine storm (it decreased ten of the most harmful cytokines, which are basically the cause for "inflammation"..)
8. Ifenprodil signficantly decreases the immune response to lung injury
9. NMDA is the receptor that Ifenprodil targets, and it blocks it. NMDA overstimulaiton can cause lung injury. Ifenprodil blocks that.
10. The authors findings indirectly suggest that this will also decrease inflammation from pulmonary fibrosis!